In this article,we will discuss about Isha Ambani’s sister-in-law’s company Piramal Pharma share price target 2024 to 2030, which has delivered robust performance in quarter 2. Quarter result details, financials, future plans, challenges based on the financials of the company and various reports by brokerage firms.
Quarter 2 Results
Piramal Pharma Ltd right now declared its outstanding Q2 FY25 numbers, and the Company’s stock price went up by 15% percent. The Company’s consolidated revenues came in at Rs 2,242 crore, up 17% year-on-year from Rs 1,914 crore in the corresponding quarter last year. PAT jumped by Rs 18 crores to reach Rs 23 crores, an absolute increase of 350%.
By far, the largest growth area was the Contract Development and Manufacturing Organization (CDMO) division, which saw its revenues rise by Rs 192 crore to Rs 816 crore from Rs 624 crore in the previous year.
| Sep’24 (Cr) | YoY Change | QoQ Change | |
|---|---|---|---|
| Sales | 2,241 | 17.28% | 14.89% |
| Operating Profit | 341 | 28.6% | 67.05% |
| Net profit | 22.59 | 350% | 125% |
Industry Overview
Piramal Pharma was engaged in the Pharmaceuticals and wellness business, offering generic APIs, sterile fill-finish solutions, and specialized services for complex hospital generics. The competition within this specific industry is immense, many regulations have to be followed, and the need for changes is present at all times.
The global industry of pharmaceuticals is anticipated to maintain its upward trend in the future due to escalating demand for its products, innovations in the health sector, and the growing cases of diseases requiring lifelong medication.
Company Overview
Piramal Pharma Ltd is a member of the Piramal Group which is a diversified global business enterprise. Nandini Piramal and the Managing Director chair the Company is Madhukar Gangadhikar. With 17 development and manufacturing sites, Piramal Pharma delivers its services to more than 100 countries worldwide.
The business aims to provide quality products and services to its customers by remodelling its products and services. It boasts an unequalled range of APIs, formulations, and healthcare solutions addressing the various therapeutic segments and other market segments.
Financials of Piramal Pharma
Currently, Piramal Pharma Ltd comes across as a financially sound company with good revenue growth and sound profitability. Key financial metrics include:
- Market Capitalization: Rs 33,250 crore
- Revenue (FY2025): Rs 86.97 billion
- Net Income (FY2025): Rs 453.30 million
- EBITDA Margin: 18%
The financials have been relayed to me by the Board of Piramal Pharma that demonstrate that the Company is in the strategic market leader position and how the Company has been able to manage its expenses. The Company’s strategic objectives to Mickey’s high-growth segments. This includes the CDMO sector has boosted the Company’s revenues and created better profit margins.
Piramal Pharma share price target 2024
In Piramal Pharma, practical research and development should be done consistently to discover new techniques of production and launch a new product to compete effectively.
| 2024 | Minimum Share Price | Maximum Share Price |
|---|---|---|
| 1st Price Target | 210 | 262 |
| 2nd Price Target | 222 | 275 |
Piramal Pharma share price target 2025
Piramal Pharma has a significant challenge mainly because the industry involves a heavy capital investment in research and development as well as in the manufacture of the products, thus putting lots of pressure on the available financial capital, more so during a recession.
| 2025 | Minimum Share Price | Maximum Share Price |
|---|---|---|
| 1st Price Target | 332 | 474 |
| 2nd Price Target | 355 | 495 |
| Join our WhatsApp Channel for latest updates | Stockmoodys |
Piramal Pharma share price target 2026
The need for better, cheaper, and more accessible pharmaceuticals products has undoubtedly increased and offered a great opportunity to and companies such as Piramal Pharma.
| 2026 | Minimum Share Price | Maximum Share Price |
|---|---|---|
| 1st Price Target | 765 | 782 |
| 2nd Price Target | 810 | 834 |
Piramal Pharma share price target 2030
A robust international operation continues to minimise market risk and diversify sources of income across different geographical locations.
| 2030 | Minimum Share Price | Maximum Share Price |
|---|---|---|
| 1st Price Target | 1452 | 1555 |
| 2nd Price Target | 1570 | 1622 |
Piramal Pharma share price target 2035
Market competition is high within the pharmaceutical industries; hence, eating into market share and pricing strategies demands innovation and efficiency.
| 2030 | Minimum Share Price | Maximum Share Price |
|---|---|---|
| 1st Price Target | 5473 | 5520 |
| 2nd Price Target | 5562 | 5605 |
Strengths of Piramal Pharma:
- Strong Growth Momentum: Sustained revenues and improvements in the net profits underscore the Company’s market position plus growth strategies.
- Robust Performance in the CDMO Segment: The CDMO segment has been postulated to have contributed significantly towards causing the Company’s sales increase.
- Strategic Cost Optimizations and Favorable Revenue Mix: Others include effective management of the various costs with a special focus on the efforts to raise the operating margins from the higher margin products, which have, in turn, boosted the overall financial position of the Company.
Weaknesses of Piramal Pharma:
- High PE Ratio Indicating Overvaluation: The P/E ratio of the company investors is high, meaning that this stock may be overpriced for concerned investors, hence posing a significant problem to investors.
- Profit to Loss Companies: Certain divisions or divisions may still be in the internet earnings phase, making losses and thus influencing overall profitability.
- Regulatory Risks: Working in an industry that is partially regulated, the shift from one regulation to another often influences the operations and revenues.
Futures perspective of Piramal Pharma
Current operations have set the goal of reaching a revenue of $2 billion along with an EBITDA of 25% by the Fiscal Year 2030. The Company plans to invest $80 million in sterile fill-finish capabilities at Lexington; it intends to grow its capability twice by now FY27. The same applies to the acquisitions partnership Piramal Pharma, which is focused on acquisitions and partnerships that are within the Company’s competence and will help drive growth.
Currently, the Company also expects to step up its research expenditure and develop new medicine that would adequately address the emerging healthcare challenge and remain relevant.
Conclusion
Piramal Pharma Ltd has been positive on its financial performance and overall growth prospects, and therefore it will be of investors’ interest to keep an eye on it. This is why, with a wide range of products, locations across the world and an emphasis on development, the Company is ready for further expansion.
Nevertheless, potential investors may be discouraged by the high PE ratio, regulatory risks, and capital intensity of this business. Piramal Pharma’s strategic directions and focus on quality and innovation shall prove essential for continued growth and, thereby, success.
| Waaree Energies IPO: Fundamental, Challenges, future plans and more… | Read More |
Disclaimer: I am not a SEBI-registered investment adviser or research analyst. The information shared is only for educational purposes. This is not investment advice.
Should you invest in Piramal Pharma?
This is an exciting stock because it does exemplary financials, often having a potential for significant growth, such as Piramal Pharma. However, it would be wise to do prior research or even consult your financial advisor to know if it will work well in investment and your risk level.
Is there growth for Piramal Pharma to reflect a multi-bagger?
This tells us that the business is competitive, offers products in multiple categories and has good growth prospects, which could result in a multi-bagger in the making – Piramal Pharma. But, accurate stock performance forecasts are always unpredictable, and the results also depend on the market conditions and the performance of the particular Company’s plans.
Currently, who owns Piramal Pharma?
Piramal Pharma Ltd is an integrated part of the Piramal Group which is a global conglomerate with business operations. It is a holding company owned by the Piramal family and Nandini Piramal is the chairperson of this Company.
Is Piramal Pharma debt-free?
Debt-free, Piramal Pharma is not, but it operates a low-debt financial model, which is a good sign for potential investors. The only minuses that can be discussed in the balance sheet of the Company are the recorded debts, though they are not critical, taking into account the Company’s stellar financial and operating results.
What is Piramal Pharma’s offering?
Piramal Pharma’s speciality business segments cover an extensive range of pharmaceuticals which include the generic APIs, Sterile fill finish solutions, and Complex hospital generics. The company product profile is extensive to serve the demands of different therapeutic segments of the market.